Silverback starts to slowly edge out of stealth mode — but there’s still plenty being kept under wraps
Silverback Therapeutics was one of those stealthy biotechs that some tech writers loved to try and track. The company surfaced when backers recruited a high profile CEO, Eric Dobmeier, out of Seattle Genetics’ c-suite. And the Form D money filed at the SEC made it look even more interesting as they tried to fill in the missing pieces of the puzzle.
This morning, Silverback — after getting started 2 years ago — is emerging from the mist.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.